- Product
- Actinum is a troublemaker?
- by Kim JiEun Feb 7, 2022 05:57am
- Actinum is out of stock due to lack of inventory. The key is to return distribution inventory after the 11th. Multivitamin Actinum, which ambitiously entered Korea, is in a position to become a headache. It is not expected to be easy to order at pharmacies for the time being. According to an official at Dongwha Pharm on the 14th, Actinum'
- Company
- Lorviqua can be prescribed at general hospitals
- by Eo, Yun-Ho Feb 4, 2022 05:57am
- Preparations have begun for the prescription of Lorviqua, a third-generation ALK that seeks to register insurance benefits. According to related industries, Lorviqua of Pfizer Korea passed DC of medical institutions such as Gangnam Severance Hospital, National Cancer Center, Chung-Ang University Hospital, and Hanyang University Hospital, as w
- Opinion
- [Reporter’s View] Mutual understanding is required
- by Kim, Jin-Gu Feb 4, 2022 05:57am
- The National Health Insurance Service made a pre-announcement for the amendment of the detailed guidelines of the ‘Price-Volume Agreement.’ The Price-Volume Agreement, or PVA, is a system that discounts a drug’s price by up to 10% through negotiation between the pharmaceutical company and NHIS for products whose use volume had rapidly
- Company
- SK Bioscience appoints former BMS lead Pa-leun Kim as VP
- by Eo, Yun-Ho Feb 4, 2022 05:57am
- SK Bioscience is making continued efforts to strengthen the company’s capability by recruiting talents to make the leap forward and become a global vaccine company. According to industry sources, SK Bioscience appointed Pa-leun Kim (44), former Lead at Bristol-Myers Squibb Korea, as its Vice President of Communication and Government Af
- Policy
- Janssen Korea has obtained permission
- by Lee, Tak-Sun Feb 4, 2022 05:56am
- Janssen Korea has been approved by the MFDS for Pharmaceutical Consignment Permission for Manufacturing Business. This can be interpreted as part of the withdrawal of the Hyangnam plant. If Janssen Korea completely withdraws its Hyangnam plant, there will be no Janssen Korea plant facilities in Korea. The MFDS approved the "Manufacturing B
- Company
- Organon Korea's Cozaar XQ will be resupplied
- by Feb 4, 2022 05:56am
- Original product for Losartan can be reproduced and prescribed in early February. Organon's HTN treatment Cozaar XQ, which was suspended due to detection of impurities above the standard last year, will be resupplied at the end of this month. Organon (CEO Kim So-eun) announced on the 27th that it will be able to re-supply Cozaar XQ from th
- Company
- Sales of Statin/Ezetimibe have surpassed ₩600 billion
- by Chon, Seung-Hyun Feb 3, 2022 05:57am
- In the dyslipidemia treatment market, a combination of Statin + Ezetimibe is gaining explosive popularity. The annual prescription market has more than quadrupled over the past five years, exceeding 600 billion won. Rosuvastatin +Ezetimibe is leading the market growth. According to UBIST, a pharmaceutical research institute, the amount of outpa
- InterView
- Era of ₩30 bil novel homegrown drug Suganon begins now
- by Feb 3, 2022 05:57am
- Annual sales of the 26th homegrown new drug ‘Suganon (evogliptin)’ family that was developed by Dong-A ST has reached &8361;30 billion 5 years into its release. During an interview with Dailypharm, Sung-Woo Lee, the GPM who oversees the marketing of Suganon, said, “Market share of Suganon has been steadily increasing due to its superio
- Policy
- 45 generics of Dapagliflozin+Sitagliptin were approved
- by Lee, Tak-Sun Feb 3, 2022 05:57am
- Dapagliflozin+Sitaglipin from 45 companies, which can only be sold in September next year, has been approved. Analysts say that the number of licensed companies is increasing as Dongkoo and Daewon, which succeeded in developing products, start supplying generics. On the 28th, the MFDS approved 13 additional items of Dapagliflozin+Sitaglipti
- Company
- Hepatitis C market in decline due to superior treatment
- by Ji Yong Jun Feb 3, 2022 05:56am
- The hepatitis C treatment market had contracted for two consecutive years since 2020. The annual decline in the number of hepatitis C patients and the introduction of effective drugs is analyzed to have caused the contraction. According to the market research institution UBIST on the 29th, outpatient prescription of hepatitis C treatments rec
